Primary femoro-popliteal-tibiofibular bypass in patients with critical limb ischemia in the era of endovascular surgery
- Authors: Burov A.Y.1, Lysenko E.R.1, Gryaznov O.G.1, Gulyaeva E.V.1, Abasov R.B.1, Knyazeva K.A.1, Malyutina E.D.1, Islyamov E.R.1
-
Affiliations:
- Federal Clinical Center for High Medical Technologies of the Federal Medical and Biological Agency
- Issue: Vol 16, No 3 (2025)
- Pages: 30-37
- Section: Original Study Articles
- URL: https://journals.rcsi.science/clinpractice/article/view/352028
- DOI: https://doi.org/10.17816/clinpract690296
- EDN: https://elibrary.ru/SGMBVH
- ID: 352028
Cite item
Abstract
BACKGROUND: In the majority of patients with critical ischemia in the lower limbs, the findings include the «multi-level» atherosclerotic lesions in the arteries of the femoral-popliteal-tibiofibular segment. The optimal method of re-vascularisation in this cohort of patients is not defined as of today. AIM: To evaluate the efficiency of conducting the initial autovenous tibiofibular bypass surgery in case of lesions in the arteries of the femoral-popliteal-tibiofibular segment in patients with critical ischemia of the lower limbs. METHODS: The analysis included the results of the initial tibiofibular autovenous bypass surgeries, performed in 112 patients at the Federal State Budgetary Institution «Federal Clinical Center of High Medical Technologies» under the Russian Federal Medical-Biological Agency during the period from 2010 until 2021, of which 25 (22.3%) individuals had the stage III chronic arterial insufficiency in the lower limbs, 87 (77.7%) — stage IV acc. to the Fountain–Pokrovsky classification. The distribution by the atherosclerotic lesion in arteries of the lower limbs with taking into consideration the TASC II classification was the following: type C — in 9 (8.0%), type D — in 103 (92.0%). RESULTS: Within the 30 days period, 4 (3.6%) patients have shown the presence of unfavorable cardio-vascular events, 3 (2.7%) cases resulted in the early high amputation. The perioperative mortality rate was 2.7% (n=3). The primary passability of the tibiofibular autovenous bypass was 91%, 76% and 67% in 1, 3 and 5 years, while the secondary passability was 93%, 80% and 71%; the limb survival rate was 98%, 86% and 81,5%; the overall survival of the patients was 88.5%, 81% and 70%, respectively. CONCLUSION: The initial tibiofibular autovenous bypass surgeries (bypass first) represent the effective and safe method of surgical treatment for atherosclerotic lesions in the arteries of the femoral-popliteal-tibiofibular segment in patients with critical ischemia of the lower limbs. Open-access surgeries in the era of endovascular surgery can be used as the first line therapy with comparable direct and remote results.
Full Text
##article.viewOnOriginalSite##About the authors
Alexander Yu. Burov
Federal Clinical Center for High Medical Technologies of the Federal Medical and Biological Agency
Author for correspondence.
Email: burovalexander93@yandex.ru
ORCID iD: 0000-0002-8414-6810
SPIN-code: 5406-0730
Russian Federation, 15A Ivanovskaya st, Khimki, Moscow region, 141435
Evgenii R. Lysenko
Federal Clinical Center for High Medical Technologies of the Federal Medical and Biological Agency
Email: angioler@mail.ru
ORCID iD: 0000-0002-0628-7378
SPIN-code: 6274-0640
MD, PhD
Russian Federation, KhimkiOleg G. Gryaznov
Federal Clinical Center for High Medical Technologies of the Federal Medical and Biological Agency
Email: zigphrid@yandex.ru
ORCID iD: 0000-0002-2286-3419
SPIN-code: 9664-0255
MD, PhD
Russian Federation, KhimkiElena V. Gulyaeva
Federal Clinical Center for High Medical Technologies of the Federal Medical and Biological Agency
Email: strelochka_l@mail.ru
ORCID iD: 0000-0002-9577-3414
SPIN-code: 2088-7527
Russian Federation, Khimki
Radzhab B. Abasov
Federal Clinical Center for High Medical Technologies of the Federal Medical and Biological Agency
Email: abasov_119@mail.ru
ORCID iD: 0009-0004-8313-8677
Russian Federation, Khimki
Karina A. Knyazeva
Federal Clinical Center for High Medical Technologies of the Federal Medical and Biological Agency
Email: knyazeva.carina@gmail.com
ORCID iD: 0009-0005-2079-6645
SPIN-code: 4238-2538
Russian Federation, Khimki
Elena D. Malyutina
Federal Clinical Center for High Medical Technologies of the Federal Medical and Biological Agency
Email: edmalutina@yandex.ru
ORCID iD: 0009-0008-2780-3504
SPIN-code: 1310-8994
MD, PhD
Russian Federation, KhimkiEmil R. Islyamov
Federal Clinical Center for High Medical Technologies of the Federal Medical and Biological Agency
Email: islyamov.emil.99@mail.ru
ORCID iD: 0009-0009-3294-1538
SPIN-code: 4800-3150
Russian Federation, Khimki
References
- GBD 2019 Peripheral Artery Disease Collaborators. Global burden of peripheral artery disease and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease study 2019. Lancet Glob Health. 2023;11(10):e1553–e1565. doi: 10.1016/S2214-109X(23)00355-8
- Lin J, Chen Y, Jiang N, et al. Burden of peripheral artery disease and its attributable risk factors in 204 countries and territories from 1990 to 2019. Front Cardiovasc Med. 2022;9:868370. doi: 10.3389/fcvm.2022.868370 EDN: ABVZUS
- Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. doi: 10.1016/j.jacc.2020.11.010 EDN: IQJFIO
- Sigvant B, Lundin F, Wahlberg E. The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2016;51(3):395–403. doi: 10.1016/j.ejvs.2015.10.022 EDN: CYANPM
- Simon F, Oberhuber A, Floros N, et al. Pathophysiology of chronic limb ischemia. Gefasschirurgie. 2018;23(Suppl 1):13–18. doi: 10.1007/s00772-018-0380-1 EDN: ZMSEOK
- Fabiani I, Calogero E, Pugliese NR, et al. Critical limb ischemia: a practical up-to-date review. Angiology. 2018;69(6):465–474. doi: 10.1177/0003319717739387
- Anand SS, Caron F, Eikelboom JW, et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol. 2018;71(20):2306–2315. doi: 10.1016/j.jacc.2018.03.008 EDN: VTHMBQ
- Agnelli G, Belch JJ, Baumgartner I, et al. Morbidity and mortality associated with atherosclerotic peripheral artery disease: a systematic review. Atherosclerosis. 2020;293:94–100. doi: 10.1016/j.atherosclerosis.2019.09.012 EDN: RDYDUP
- Van Netten JJ, Fortington LV, Hinchliffe RJ, Hijmans JM. Early post-operative mortality after major lower limb amputation: a systematic review of population and regional based studies. Eur J Vasc Endovasc Surg. 2016;51(2):248–257. doi: 10.1016/j.ejvs.2015.10.001
- Conte MS, Bradbury AW, Kolh P, et al.; GVG Writing Group. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6S):3S–125S.e40. doi: 10.1016/j.jvs.2019.02.016 EDN: ZWNXMR
- The TASC Steering Committee; Jaff MR, White CJ, Hiatt WR, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II). J Endovasc Ther. 2015;22(5):663–677. doi: 10.1177/1526602815592206
- Farber A, Menard MT, Conte MS, et al.; BEST-CLI Investigators. Surgery or endovascular therapy for chronic limb-threatening ischemia. N Engl J Med. 2022;387(25):2305–2316. doi: 10.1056/NEJMoa2207899 EDN: VBMMRU
- Bradbury AW, Moakes CA, Popplewell M, et al.; BASIL-2 Investigators. A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial. Lancet. 2023;401(10390):1798–1809. doi: 10.1016/S0140-6736(23)00462-2
- Norgren L, Patel MR, Hiatt WR, et al. Outcomes of patients with critical limb ischaemia in the EUCLID trial. Eur J Vasc Endovasc Surg. 2018;55(1):109–117. doi: 10.1016/j.ejvs.2017.11.006 EDN: YDSBZB
- Uccioli L, Meloni M, Izzo V, et al. Critical limb ischemia: current challenges and future prospects. Vasc Health Risk Manag. 2018;14:63–74. doi: 10.2147/VHRM.S125065
- Biancari F, Salenius JP, Heikkinen M, et al. Risk-scoring method for prediction of 30-day postoperative outcome after infrainguinal surgical revascularization for critical lower-limb ischemia: a finnvasc registry study. World J Surg. 2007;31(1):217–225; discussion 226-227. doi: 10.1007/s00268-006-0242-y EDN: PTNLOC
- Simons JP, Schanzer A, Flahive JM, et al. Survival prediction in patients with chronic limb-threatening ischemia who undergo infrainguinal revascularization. Eur J Vasc Endovasc Surg. 2019;58(1S):120–134. doi: 10.1016/j.ejvs.2019.04.009
Supplementary files






